MedPath

Intermittent Oral-esophageal Tube Feeding in Alzheimer's Patients With Dysphagia

Not Applicable
Withdrawn
Conditions
Alzheimer Disease
Interventions
Behavioral: Conventional Care
Device: Intermittent Oral-esophageal Tube Feeding
Device: Nasogastric tube
Registration Number
NCT06220292
Lead Sponsor
Zeng Changhao
Brief Summary

This is a prospective multicenter study with Alzheimer's patients with dysphagia. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oral-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared.

Detailed Description

The Alzheimer's disease in the elderly exhibits the high prevalence.This is a prospective multicenter study with Alzheimer's patients with dysphagia. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oral-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • age between 18 years and 85 years, meeting the diagnosis of Alzheimer's Disease.
  • presence of no contraindication for enteral nutrition.
  • with dysphagia verified by Imaging materials.
  • with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications
  • Minimum Mental State Examination ranging from 10-26
Exclusion Criteria
  • unable to cooperate in completing treatment and assessment due to personal reasons or other disorders.
  • complicated with other intracranial lesions, such as stroke.
  • abnormal structure of swallowing-related organ and tissue.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
The control groupConventional CareDuring the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
The observation groupIntermittent Oral-esophageal Tube FeedingDuring the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
The observation groupConventional CareDuring the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
The control groupNasogastric tubeDuring the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
Primary Outcome Measures
NameTimeMethod
Hemoglobinday 1 and day 15

Hemoglobin was recorded through the blood routine test. (Hb, g/L)

Serum albuminday 1 and day 15

Serum albumin was recorded through the blood routine test. (ALB, g/L)

Total serum proteinday 1 and day 15

Total serum protein was recorded through the blood routine test. (TP, g/L)

Serum prealbuminday 1 and day 15

Serum prealbumin was recorded through the blood routine test.(PA, g/L)

Secondary Outcome Measures
NameTimeMethod
Body Mass Indexday 1 and day 15, day 45, day 105, day 195

Body Mass Index was assessed with the combination of body weight and height: weight (kg)/ \[height (m)\] \^2

Pulmonary Infectionsday 1 and day 15, day 45, day 105, day 195

During the treatment, the occurrence of complications was recorded for both groups. These complications included but were not limited to: 1) Pulmonary Infections: Monitoring for the development of respiratory infections such as pneumonia or bronchitis.

Video Fluoroscopic Swallowing Studyday 1 and day 15

Video Fluoroscopic Swallowing Study, which is considered as the "gold standard", swallowing process is divided into four periods: cognitive, oral, pharyngeal, and esophageal periods with a total score of 10 and a higher score indicates better swallowing ability (less dysphagia).

Mini Nutritional Assessmentday 1, day 45, day 105, day 195

Mini Nutritional Assessment is used for assessment of nutritional status, ranging 0 to 30. A higher score indicates the better nutritional status

Trial Locations

Locations (1)

Zheng Da first Yuan Hospital

🇨🇳

Zhengzhou, Henan, China

© Copyright 2025. All Rights Reserved by MedPath